CANF Stock Forecast & Price Target

Can Fite Biopharma is a clinical-stage biopharmaceutical company focused on developing small-molecule drugs that target the A3 adenosine receptor for cancer, inflammatory diseases, and liver disorders. With strong clinical data from Phase II and III trials for Namodenoson in hepatocellular carcinoma and Piclidenoson in psoriasis, a 30% discount rate, and a diverse pipeline, Can Fite should expect strong future revenues with a valuation of $7.0 per share. The recent reverse stock split has allowed investors to refocus on the company's promising clinical pipeline, and the advancement of Namodenoson into a Phase 2b pancreatic cancer combination study reinforces the company's potential in a difficult disease setting. Additionally, a 12-month price target of $5.00 per ADS is justified based on a risk-adjusted net present value analysis and projected future revenues through 2032. Though risks such as commercial, clinical, regulatory, and legal remain, the company's strong financials and pipeline potential outweigh these concerns.

Can Fite Biopharma is a clinical-stage biopharmaceutical company with a pipeline of drugs targeting the A3 adenosine receptor for various diseases. However, the company has a negative outlook due to its limited revenue and high expenses, with a net loss of $3.7 million in the third quarter of 2020 and a total net loss of $76.4 million since inception. In addition, the company's reliance on a single drug (Namodenoson) and the limited success in clinical trials raises concerns about the company's long-term growth and profitability. Furthermore, with only $3.4 million in cash and cash equivalents as of September 30, 2020, the company may struggle to fund its operations and continue developing its pipeline.